---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-053575"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T07:13:42.415932+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q4 net loss $13.8M ($0.06/shr); cash $611.2M; pipeline advances for NUV-868 and NUV-1511

## Summary
- Q4 net loss $13.8M ($0.06/shr); full-year net loss $75.8M, improved from $104.2M in 2022.
- Cash, equivalents and marketable securities $611.2M at Dec 31, 2023.
- Completed NUV-868 Phase 1 monotherapy, determined MTD; Phase 1b combo studies (olaparib/enzalutamide) ongoing.
- FDA cleared IND for NUV-1511, first DDC candidate; Phase 1/2 study expected to start H1 2024.
- Appointed Dr. Robert Mashal to Board of Directors.

## SEC filing metadata
- accession: 0001193125-24-053575
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312524053575/0001193125-24-053575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312524053575/d786844d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-053575
- JSON: https://secwatch.observer/filing/0001193125-24-053575.json
- Plain text: https://secwatch.observer/filing/0001193125-24-053575.txt

## Key facts
- Earnings Releases
  Nuvation Bio Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net loss of $13.8 million, or $(0.06) per share, EPS $(0.06) per share.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: net loss of $13.8 million, or $(0.06) per share
  - EPS: $(0.06) per share
  - Result: reported results
  source text: Nuvation Bio reported a net loss of $13.8 million, or $(0.06) per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811063/000119312524053575/0001193125-24-053575-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.